Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment

Executive Summary

Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.

You may also be interested in...



UK’s NICE Slashes HTA Appraisal Time For Ngenla & Ofev Using New Approach

Ngenla and Ofev are the first two drugs to be evaluated using the health technology appraisal institute’s new proportionate approach – they were both appraised much faster than usual.

New German Law Gives Payers More Power Over Drug Pricing

A new law aimed at limiting drug spending in Germany will mean that only companies with new products that offer high levels of added benefit will have full flexibility to negotiate prices.

Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body

Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel